Pancreatic cancer
Prestige Biopharma Ltd is conducting clinical research in advanced and/or metastatic pancreatic adenocarcinoma, with a focus on patients whose disease has progressed after prior chemotherapy. The programme includes investigation of an oncology treatment given alone and in combination with gemcitabine for locally advanced and metastatic disease.
- Pancreatic adenocarcinoma
- Metastatic disease
- Combination therapy
The sponsor’s oncology portfolio in this area centres on treatment options for difficult-to-manage pancreatic malignancy in the Singapore research setting.
Oncology treatment development
The company is also active in early clinical evaluation of a novel oncology agent intended for patients with solid tumours, with particular attention to safety, tolerability, and treatment activity in a refractory cancer population.
- Solid tumour oncology
- Refractory cancer
- Therapeutic combination strategies
This reflects a research interest in expanding treatment choices for advanced cancer care through clinical investigation of new biologic or targeted approaches.
Biosimilar and immunology research
Prestige Biopharma Ltd is involved in comparative clinical research for a biosimilar programme, examining pharmacokinetics and safety in healthy volunteers. The work is aligned with the development of immune-mediated disease therapies and biologic medicines.
- Biosimilar medicines
- Pharmacokinetic evaluation
- Healthy volunteer studies
The sponsor’s activity in this domain supports clinical assessment of biologic comparability and tolerability in a controlled research population.
Clinical research operations
The sponsor’s studies are concentrated across a small network of research sites in Singapore, with ongoing recruitment across both oncology and non-patient volunteer studies. The portfolio spans treatment-focused and comparative biologic research within a single-country setting.
- Single-country trial activity
- Recruiting studies
- Multi-site collaboration
These activities place emphasis on clinical development in Asia, particularly where oncology and biologic medicine programmes intersect.
